FDA Cleared First Prime Medicine Genetic Therapy Trial
The regulatory approval permits clinical testing of an in vivo gene editing approach for Alpha-1 Antitrypsin Deficiency.
Updated on Sept. 24, 2026 in Biotech
Live Poll
Do you trust new genetic therapies to effectively treat inherited diseases in the long term?
The FDA has cleared Prime Medicine to begin a first-in-human clinical trial for PM647, an investigational Prime Editor genetic therapy. This in vivo treatment is designed to address Alpha-1 Antitrypsin Deficiency by correcting a specific gene mutation.
Why it matters
PM647 aims to restore the production of functional M-AAT protein in patients with Alpha-1 Antitrypsin Deficiency by correcting the E342K mutation in the SERPINA1 gene. This development marks the transition of the company's gene editing platform into initial clinical human testing.
PM647 uses a liver-directed lipid nanoparticle to deliver an in vivo Prime Editor, a technology designed to make precise DNA corrections within the body. The approach replaces the standard E342K mutation with a functional gene sequence, aiming to treat approximately 100,000 U.S. patients.
The players
Prime Medicine
A Cambridge, Massachusetts-based biotechnology company focused on developing gene editing therapies using its proprietary Prime Editing platform.
FDA
The United States federal agency responsible for regulating new medical treatments and clinical trial applications.
The details
The treatment is administered as a one-time intravenous infusion. The Phase 1/2 study is a global, single-arm, open-label trial focused on evaluating safety, tolerability, and preliminary clinical efficacy. Initially, enrollment will be restricted to adults exhibiting lung-only manifestations of the deficiency, with plans to include adults with liver disease once tolerability is established.
Timeline
September 24, 2026: The FDA officially cleared the Investigational New Drug application for PM647.
2027: Initial clinical trial data is expected to be released.
The Tech Race
This trial marks a progression in the broader competitive race to advance in vivo genetic medicine beyond current gene-addition methods. It establishes a clinical baseline for Prime Medicine as it attempts to demonstrate that its gene-editing precision can safely address genetic deficiencies.
This study is initially limited to adults with lung-only manifestations of Alpha-1 Antitrypsin Deficiency within the United States. Future patient access will depend on the demonstration of safety and clinical efficacy in this initial human trial phase.
The takeaway
This trial is a critical milestone for testing whether precision genome editing can safely replace defective protein production in patients. Researchers and investors will be looking toward the 2027 data release to gauge the initial safety profile of the liver-directed delivery method.
What happens next
Initial clinical trial data is expected to be reported in 2027.
Further reading
For broader trends in the industry, see the Biotech section.
Live Poll
Do you trust new genetic therapies to effectively treat inherited diseases in the long term?
